Peregrine Capital Management LLC trimmed its position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 12.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,859 shares of the biotechnology company’s stock after selling 5,124 shares during the quarter. Peregrine Capital Management LLC owned about 0.05% of GALAPAGOS NV/S worth $6,877,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the business. Citigroup Inc. increased its holdings in shares of GALAPAGOS NV/S by 1,972.7% during the first quarter. Citigroup Inc. now owns 104,796 shares of the biotechnology company’s stock valued at $20,531,000 after acquiring an additional 99,740 shares in the last quarter. Norges Bank acquired a new position in shares of GALAPAGOS NV/S during the fourth quarter valued at about $14,478,000. Morgan Stanley increased its holdings in shares of GALAPAGOS NV/S by 68.0% during the first quarter. Morgan Stanley now owns 121,181 shares of the biotechnology company’s stock valued at $23,742,000 after acquiring an additional 49,053 shares in the last quarter. BlackRock Inc. increased its holdings in shares of GALAPAGOS NV/S by 11.4% during the first quarter. BlackRock Inc. now owns 317,648 shares of the biotechnology company’s stock valued at $62,234,000 after acquiring an additional 32,416 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of GALAPAGOS NV/S by 61.2% during the first quarter. Acadian Asset Management LLC now owns 74,126 shares of the biotechnology company’s stock valued at $14,523,000 after acquiring an additional 28,146 shares in the last quarter. 11.71% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:GLPG opened at $184.14 on Friday. GALAPAGOS NV/S has a 1 year low of $112.00 and a 1 year high of $274.03. The firm has a market capitalization of $12.02 billion, a price-to-earnings ratio of 35.34 and a beta of 1.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The business’s 50 day moving average price is $199.62 and its 200-day moving average price is $209.85.
GALAPAGOS NV/S (NASDAQ:GLPG) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.09. GALAPAGOS NV/S had a return on equity of 12.45% and a net margin of 15.42%. The firm had revenue of $117.93 million for the quarter, compared to analyst estimates of $121.39 million. On average, sell-side analysts expect that GALAPAGOS NV/S will post -1.5 earnings per share for the current year.
Several equities analysts recently weighed in on GLPG shares. Royal Bank of Canada reiterated a “hold” rating and issued a $155.00 price target on shares of GALAPAGOS NV/S in a report on Monday, April 13th. Nomura reiterated a “buy” rating and issued a $290.00 price target on shares of GALAPAGOS NV/S in a report on Thursday, May 21st. Morgan Stanley cut their price target on shares of GALAPAGOS NV/S from $226.00 to $224.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 15th. TheStreet downgraded shares of GALAPAGOS NV/S from a “b” rating to a “c” rating in a report on Wednesday, May 6th. Finally, UBS Group reiterated a “neutral” rating on shares of GALAPAGOS NV/S in a report on Monday, May 18th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $220.08.
GALAPAGOS NV/S Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Recommended Story: How is the LIBOR rate calculated?
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.